NCT03148990View on ClinicalTrials.gov

Study to Evaluate the Immunogenicity, Reatogenicity and Safety of Double Viral Vaccine (MR) for Measles and Rubella

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

432

Participants

Timeline

Start Date

November 20, 2018

Primary Completion Date

August 12, 2020

Study Completion Date

August 12, 2020

Conditions
RubellaMeasles
Interventions
BIOLOGICAL

Measles and Rubella vaccine

Administration of the experimental vaccine (MR).

BIOLOGICAL

Measles, Mumps and Rubella vaccine

Administration of the comparator vaccine (MMR).

Trial Locations (2)

21040900

Secretaria Municipal de Saúde do Estado do Rio de Janeiro, Rio de Janeiro

59.025-050

Centro de Estudos e Pesquisas em Moléstias Infecciosas Ltda (CPCLIN), Natal

All Listed Sponsors
collaborator

Oswaldo Cruz Institute

UNKNOWN

lead

The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)

OTHER

NCT03148990 - Study to Evaluate the Immunogenicity, Reatogenicity and Safety of Double Viral Vaccine (MR) for Measles and Rubella | Biotech Hunter | Biotech Hunter